Jasper Therapeutics (JSPR) Total Non-Current Liabilities (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Total Non-Current Liabilities of $29.3 million for Q4 2025, up 84.16% year-over-year from $15.9 million in Q4 2024, and up 25.84% quarter-over-quarter from $23.3 million in Q3 2025.
Jasper Therapeutics (JSPR) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $29.3 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 84.16% year-over-year to $29.3 million; the TTM figure through Dec 2025 stood at $29.3 million (up 84.16% YoY), while the FY2025 annual figure was $29.3 million, up 84.16% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $29.3 million, up from $23.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $29.3 million in Q4 2025, with the low at $3.7 million in Q1 2021.
- The 5-year median for Total Non-Current Liabilities is $13.5 million (2024), against an average of $15.2 million.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities soared 501.32% in 2021, then slumped 59.15% in 2022.
- Jasper Therapeutics' Total Non-Current Liabilities stood at $23.5 million in 2021, then sank by 47.41% to $12.4 million in 2022, then climbed by 14.85% to $14.2 million in 2023, then grew by 12.24% to $15.9 million in 2024, then surged by 84.16% to $29.3 million in 2025.
- Business Quant data shows JSPR's Total Non-Current Liabilities at $29.3 million in Q4 2025, $23.3 million in Q3 2025, and $20.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | 7.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.33 Mn |
| Sep 30, 2025 | 23.31 Mn |
| Jun 30, 2025 | 20.70 Mn |
| Mar 31, 2025 | 13.09 Mn |
| Dec 31, 2024 | 15.93 Mn |
| Sep 30, 2024 | 13.47 Mn |
| Jun 30, 2024 | 13.60 Mn |
| Mar 31, 2024 | 12.71 Mn |
| Dec 31, 2023 | 14.19 Mn |
| Sep 30, 2023 | 16.24 Mn |
| Jun 30, 2023 | 13.60 Mn |
| Mar 31, 2023 | 12.78 Mn |
| Dec 31, 2022 | 12.35 Mn |
| Sep 30, 2022 | 11.44 Mn |
| Jun 30, 2022 | 11.06 Mn |
| Mar 31, 2022 | 11.84 Mn |
| Dec 31, 2021 | 23.49 Mn |
| Sep 30, 2021 | 28.01 Mn |
| Jun 30, 2021 | 3.83 Mn |
| Mar 31, 2021 | 3.68 Mn |